Skip to content
Dosage GuideResearch Reference

Neuropeptide Y Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Neuropeptide Y. All information is for educational purposes only.

Quick Answer

In preclinical models, Neuropeptide Y is typically administered at doses ranging from 1-10 mcg/kg via intracerebroventricular (ICV) injection for appetite regulation studies. For anxiolytic effects, systemic doses of 50-500 mcg/kg have been explored. Due to its short half-life and limited blood-brain barrier permeability, alternative delivery methods such as intranasal administration are being researched to enhance central nervous system bioavailability. No human clinical dose-ranging trials have been completed.

→ Neuropeptide Y Benefits→ Neuropeptide Y Side Effects→ Full Neuropeptide Y Profile
Table of Contents

Standard Dosage Range

Research dosing range: 1-10 mcg/kg (ICV); 50-500 mcg/kg (systemic)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Appetite Stimulation Research

1-5 mcg/kgSingle dose
Duration

Single administration

ICV injection required for direct access to hypothalamic feeding centers. Observe food intake over several hours. Typically used in rodent models.

Anxiolytic Research

100-500 mcg/kgSingle dose
Duration

Single administration

Systemic administration (e.g., subcutaneous, intraperitoneal) may be used. Evaluate anxiety-related behaviors using standard paradigms (elevated plus maze, open field).

Stress Resilience Enhancement

50-200 mcg/kgSingle dose
Duration

Single administration

Administer prior to stressor exposure (e.g., restraint stress, social defeat). Assess stress-related hormones (cortisol) and behavioral responses.

Neuroprotection Studies

10-100 mcg/kgSingle dose
Duration

Single administration

Administer before or after experimental induction of neuronal injury (e.g., excitotoxicity, ischemia). Evaluate neuronal survival and functional outcomes.

Timing & Frequency

Due to NPY’s short half-life (~20-30 minutes), experiments typically involve single-dose administration. For appetite studies, injection occurs prior to the dark cycle (active feeding period for rodents). For stress or anxiety studies, administration precedes the stressor/behavioral test.

Cycle Guidance

NPY is not typically used in cyclical regimens due to its transient effects. Research focuses on single administrations to investigate acute effects on specific physiological parameters. Long-term safety data are lacking, precluding recommendations for chronic use.

Reconstitution Reference

Quick reference for reconstituting Neuropeptide Y. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg per vial
BAC Water Volume1 mL sterile saline or water
Concentration & Draw1 mg/mL: 1 mcg = 0.001 mL (1 unit on a 100-unit insulin syringe is 10 mcg, therefore 0.1 unit is 1 mcg)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C for long-term storage.
StabilityReconstituted solution stable up to 7 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the route of administration for NPY?
Due to its poor blood-brain barrier permeability, ICV injection is often used to target brain areas. Systemic administration (subcutaneous, intraperitoneal) can also be used, but higher doses may be required. Intranasal administration is being explored to improve brain delivery.
What is the half-life of NPY?
NPY has a short half-life of approximately 20-30 minutes in circulation.
What are the potential side effects of NPY?
Potential side effects are dose-dependent and may include changes in appetite, blood pressure, and anxiety levels. More research is needed to characterize the full safety profile in humans.

Last updated: 2026-02-19